-
Chinese eat half of gastrointestinal tumors!
Time of Update: 2021-11-02
Based on this, the researchers proposed that high BMI, red meat and processed meat consumption are the three major risk factors that cause the increasing burden of cancer in the digestive system in China .
-
Cancer Cell: Lung cancer fibroblasts influence the patient's response to treatment
Time of Update: 2021-11-02
expressionIn addition, this CAF functional classification is related to the patient's clinical response to targeted therapy and also to the tumor immune microenvironment , so it provides a way to guide personalized treatment .
-
You still get liver cancer after doing physical examinations every year, are you really doing it right?
Time of Update: 2021-11-01
Current status of liver cancer in ChinaCurrent status of liver cancer in ChinaHigh morbidity, low early diagnosis, high mortalityIn 2020, the incidence of primary liver cancer (HCC) in China ranks the fifth among malignant tumors, with 410,000 new cases, accounting for about half of the number of new patients worldwide, and the second highest mortality rate of malignant tumors, with 391,000 deaths .
-
Differential diagnosis of T1 hyperintensity liver disease
Time of Update: 2021-11-01
Washout within the solid lesionWashout within the solid lesion Carcinoid liver metastases with bleedingCarcinoid liver metastases with bleeding Carcinoid liver metastases with bleedingHemorrhagic carcinoid metastasisHemorrhagic carcinoid metastasis Hemorrhagic carcinoid metastasis ③③ ③ T1 high signal and low signal focus, T2 mixed signal, irregular ring enhancement, heterogeneous, continuous enhancementT1 high signal and low signal focus, T2 mixed signal, irregular ring enhancement, heterogeneous, continuous enhancement
-
"Xingguang Yiyi-Deep Interpretation" blood experts gather, invite you to the appointment!
Time of Update: 2021-11-01
focuses on immunotherapy, is committed to cure cancer patients, 22 June 2021, Fosun Kate CAR-T cell therapy drugs Yi Kaida ® ® (A Jilun game Injection) in the country Officially approved in 38 countries and regions, nearly 5,000 patients used an overall response rate (ORR) of 83%, a complete response (CR) rate of 58%, and a median overall survival (OS) of 25.
-
The first senile blood cancer CAR-T and the second indication of Gilead Tecartus were approved by the U.S. FDA
Time of Update: 2021-10-21
Recently, another indication for Gilead's cancer cell therapy Tecartus has been approved by the US FDA for the treatment of adult elderly acute lymphoblastic leukemia .
In March 2021, the US FDA approved Yescarta's second indication, which is mainly used for second-line or above treatment of adult patients with relapsed/refractory follicular lymphoma (FL) .
-
STTT Fuzhou University Jia Li and other teams found potential therapeutic targets for melanoma
Time of Update: 2021-10-21
Studies have shown that NOL7 has a cancer-promoting effect on the progression and metastasis of melanoma .
In summary, this study shows that NOL7 plays a cancer-promoting effect on the progression and metastasis of melanoma .
-
Chief nurse Cai Ruiqing: The infusion port can improve the compliance of children with tumor patients and is safer
Time of Update: 2021-10-21
During the conference, Yimaitong specially invited Cai Ruiqing, head nurse of the Children's Oncology Department of Sun Yat-sen University Cancer Center to share the application of the infusion port in the treatment of children's tumors .
-
Director’s question: Do you know the 6 major adverse reactions of CDK4/6 inhibitors?
Time of Update: 2021-10-21
Therefore, the possible adverse reactions of CDK4/6 inhibitors should be considered in the treatment of breast cancer, and the treatment should be actively dealt with to reduce the impact on patients .
-
Express first-line treatment of advanced liver cancer, ALK-1 monoclonal antibody/Opdivo combination is clinically approved in China
Time of Update: 2021-10-21
, announced that China National Medical Products Administration (NMPA) has recently approved its ALK-1 monoclonal antibody (GT90001C), and Bristol-Myers Squibb (BMS) anti-PD-1 monoclonal antibody A clinical trial of nivolumab (English trade name Opdivo) in combination for the treatment of patients with advanced hepatocellular carcinoma (HCC) without systemic treatment .
com/news-releases/kintor-pharma-announces-china-nmpa-approves-clinical-trial-of-alk-1-and-nivolumab-combination-therapy-for-the-first-line-treatment-of-advanced -hepatocellular-carcinoma-301396741.
-
Dialogue at the pinnacle, one hundred million ways forward-Watch the new progress of WM research, talk about the new future of "no chemotherapy" treatment
Time of Update: 2021-10-21
In order to improve the diagnosis and treatment of Waldenstrom's macroglobulinemia (WM) by clinicians in China, standardize the WM treatment plan, and strengthen the efficacy evaluation and follow-up
-
Guided ultrasound to deliver drugs to metastatic brain lesions in breast cancer patients｜《Science·Translational Medicine》
Time of Update: 2021-10-21
Click on the blue text above to follow our study of four Her2-positive breast cancer patients with brain metastases.
Low-dose MRgFUS temporarily increases the permeability of the blood-brain barrier and can be precisely positioned to open up treatment areas, such as the brain stem, cranial nucleus, and cerebellum, which are not always suitable for surgery or radiation therapy .
-
An article to understand new drug treatments for marginal zone lymphoma
Time of Update: 2021-10-21
Related studies have explored the efficacy of PI3K inhibitors Idelalisib, Duvelisib, Copanlisib, Parsaclisib and Umbralisib in patients with R/R indolent lymphoma (including R/R MZL patients) .
The results of the study showed that the ORR of Copanlisib treatment of R/R MZL patients was 78%, and the CR rate was 13% .
-
[Research] The application of "artificial intelligence + biomedicine" to liver cancer with a high mortality rate is expected to revolutionize the diagnosis and treatment of cancer in the future!
Time of Update: 2021-10-21
Researchers at King's College Hospital in London and Queen Mary University of London have demonstrated that a new computer-based algorithm can reduce the growth of cancer cells based on drugs used to treat primary liver cancer.
-
2021 CSCO Professor Sheng Xinan: Immunization combined with ADC, a new breakthrough in the treatment of metastatic urothelial cancer
Time of Update: 2021-10-21
. Yimaitong: At this year’s CSCO meeting, you reported a Phase 1B/II clinical study on the safety and effectiveness of vedicitumumab combined with teriprizumab in the treatment of patients with locally advanced or metastatic urothelial cancer Please introduce the latest data of this study.
-
CheckMate 142 study nivolumumab + low-dose ipilimumab first-line treatment of MSI-H/dMMR metastatic colorectal cancer results announced tumor information
Time of Update: 2021-10-21
*Only for medical professionals to read for reference, 1 minute a day, to give you professional "talking information" in the tumor circle! (If you need the original text of the literature, you can ad
-
New guidelines, new journey: China's AML diagnosis and treatment guidelines will be released in 2021!
Time of Update: 2021-10-21
Pioneering and innovative to realize the progress from the international "following" to "parallel running" Professor Wang Jianxiang said that the new version of the guideline plays a standard role in the clinical diagnosis and treatment of AML, but outside the guideline, hematologists have a very open mind and will continue to do so.
-
Pure ground glass nodules cut or not cut?
Time of Update: 2021-10-21
"Many questions about lung nodules still lack data to support Professor Wang Qun," said: "The current domestic guidelines and consensus on the diagnosis and treatment of pure ground glass nodules are relatively'advanced'.
-
Don't panic if immunotherapy fails! A new combination therapy is about to emerge, or save 80% of cancer patients
Time of Update: 2021-10-21
"Our research shows that the combination of CBX-12 and immune checkpoint inhibitors may have an effect on tumors for which immunotherapy is usually ineffective," said Dr.
Reference: [1] A peptide-drug conjugate that targets the acidic environment of cancer cells may improve the efficacy of immunotherapy.
-
[Science Sub-Journal] How to treat epigenetic mutations in children with brain tumors more effectively?
Time of Update: 2021-10-21
Now, an international research team led by the University of Michigan Health Roger Cancer Center has discovered a small molecule inhibitor that can inhibit tumor growth in this glioma animal model, and develop new and More effective treatment methods bring new hope .
